By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Astrazeneca Pharmaceuticals LP et al. v. Mylan Pharmaceuticals Inc.
1:07-cv-00177; filed December 28, 2007 in the Northern District of West Virginia
Astrazeneca Pharmaceuticals LP et al. v. Aurobindo Pharma Limited, Inc. et al.
3:07-cv-06020; filed December 18, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. RE37,314 ("Pyrimidine Derivatives," issued August 7, 2001) following a paragraph IV certification as part of Aurobindo's filing of an ANDA to manufacture a generic version of AstraZeneca's Crestor® (rosuvastatin calcium, used to treat high cholesterol). The complaints in these cases are substantially identical. View the Aurobindo complaint here.
Sepracor Inc. et al. v. Sandoz, Inc.
3:07-cv-06107; filed December 26, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 7,214,683 ("Compositions of Descarboethoxyloratadine," issued May 8, 2007) and 7,214,684 ("Methods for the Treatment of Allergic Rhinitis," issued May 8, 2007), licensed to Schering-Plough, following a paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Schering-Plough's Clarinex® (desloratidine, used to treat allergies). View the complaint here.
Santarus Inc. et al. v. Par Pharmaceutical Inc.
1:07-cv-00827; filed December 20, 2007 in the District Court of Delaware
Infringement of U.S. Patent Nos. 6,699,885 ("Substituted Benzimidazole Dosage Forms and Methods of Using Same," issued March 2, 2004), 6,489,346 (same title, issued December 3, 2002), 6,645,988 (same title, issue November 11, 2003), and 6,780,882 (same title, issued August 24, 2004) following a paragraph IV certification as part of Par's filing of an ANDA to manufacture a generic version of Santarus' Zegerid® powder for oral suspension (omeprazole/sodium bicarbonate, used to treat heartburn and other symptoms associated with gastroesophageal reflux disease). View the complaint here.
Monsanto Company et al. v. Tidball et al.
4:07-cv-02079; filed December 20, 2007 in the Eastern District of Missoui
Monsanto Company et al. v. Wagoner
1:07-cv-00952; filed December 17, 2007 in the Middle District of North Carolina
Infringement of U.S. Patent Nos. 5,352,605 ("Chimeric Genes for Transforming Plant Cells Using Viral Promoters," issued October 4, 1994) and RE39,247 ("Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate Synthases," issued August 22, 2006) based on defendant's use of soybean seed produced from earlier planted Roundup Ready® soybean seed. View the Tidball complaint here and the Wagoner complaint here.
Janssen, L.P. et al. v. KV Pharmaceutical Company
1:07-cv-00825; filed December 18, 2007 in the District Court of Delaware
Janssen, L.P. et al. v. KV Pharmaceutical Company
3:07-cv-05982; filed December 14, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 7,160,559 ("Controlled Release Galantamine Composition," issued January 9, 2007) following a paragraph IV certification as part of KV's filing of an ANDA to manufacture a generic version of Janssen's Razadyne ER® (formerly Reminyl®) (galantamine hydrobromide, used to treat mild to moderate dementia of the Alzheimer's type). The complaints in these cases are substantially identical. View the Delaware complaint here.
Comments